Deinobiotics Overview

  • Founded
  • 2009
  • Status
  • Acquired/​Merged
  • Employees
  • 3
  • Latest Deal Type
  • M&A

Deinobiotics General Information


Operator of a biotechnology platform intended to develop antibiotics and antifungals. The company's biotechnology platform provides new drugs and medicinal compounds for fighting against resistant hospital germs responsible for nosocomial infections (gram-negative bacteria and fungi), enabling clients with a new, modern and advanced way to fight hospital-acquired infections.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Drug Delivery
Other Industries
Primary Office
  • 1682 Rue de la Valsière
  • 34790 Grabels
  • France
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Deinobiotics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 04-Jan-2017 00.000 Completed Generating Revenue
5. Debt - General 00000 00.000 Completed Generating Revenue
4. Early Stage VC 00000 Completed Generating Revenue
3. Grant 22-Mar-2010 00000 Completed Generating Revenue
2. Accelerator/Incubator $535K $535K 00.000 Completed Generating Revenue
1. Grant 01-Jan-2009 $954K Completed Generating Revenue

Deinobiotics Executive Team (1)

Name Title Board Seat Contact Info
Dominique Le Beller Chief Executive Officer

Deinobiotics Former Investors (6)

To view Deinobiotics‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Bpifrance Sovereign Wealth Fund Minority 000 0000 000000 0
EUROBIOMED Other 000 0000 000000 0
European Regional Development Fund Other 000 0000 000000 0
Holdings Incubatrices Accelerator/Incubator Minority 000 0000 000000 0
Languedoc-Roussillon Region Government 000 0000 000000 0

Ready to get started?

Request a free trial